Imiglucerase

Background: Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.

Indication: For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)

A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.

Phase 4

Completed

Conditions: Gaucher Disease Type I
Clucocerebrosidase Deficiency Disease
Cerebroside Lipidosis Syndrome
Glucosylceramide Beta-Glucosidase Deficiency Disease
Gaucher Disease, Non-Neuronopathic Form

Phase 4

Completed

Conditions: Gaucher Disease, Type 1
Glucocerebrosidase Deficiency Disease
Glucosylceramide Beta-Glucosidase Deficiency Disease
Cerebroside Lipidosis Syndrome
Gaucher Disease, Non-Neuronopathic Form

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University Research Foundation for Lysosomal Storage Disease, Inc., Coral Springs, Florida, United States
🇺🇸
Midwest Cancer Research Group, Inc., Skokie, Illinois, United States

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.